The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.
The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.
Drug Review Updates
Atezolizumab (Tecentriq) for Non-Small Cell Lung Cancer
(Pending Submission as of November 17, 2017)
Dabrafenib & Trametinib (Tafinlar & Mekinist) in combo for Non-Small Cell Lung Cancer
(Notification to Implement Issued as of November 17, 2017)
Inotuzumab Ozogamicin (Besponsa) for Acute Lymphoblastic Leukemia
(Open for Input on Submission until November 27, 2017)